Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Rationale Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation and cardiovascular disease. Interaction between inflammatory cells and activated platelets is important ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...